RT Journal Article
SR Electronic
T1 A platform for brain network sensing and stimulation with quantitative behavioral tracking: Application to limbic circuit epilepsy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.09.24302358
DO 10.1101/2024.02.09.24302358
A1 Kremen, Vaclav
A1 Sladky, Vladimir
A1 Mivalt, Filip
A1 Gregg, Nicholas M.
A1 Balzekas, Irena
A1 Marks, Victoria
A1 Brinkmann, Benjamin H.
A1 Lundstrom, Brian Nils
A1 Cui, Jie
A1 St Louis, Erik K.
A1 Croarkin, Paul
A1 Alden, Eva C
A1 Fields, Julie
A1 Crockett, Karla
A1 Adolf, Jindrich
A1 Bilderbeek, Jordan
A1 Hermes, Dora
A1 Messina, Steven
A1 Miller, Kai J.
A1 Van Gompel, Jamie
A1 Denison, Timothy
A1 Worrell, Gregory A.
YR 2024
UL http://medrxiv.org/content/early/2024/04/03/2024.02.09.24302358.abstract
AB Temporal lobe epilepsy is a common neurological disease characterized by recurrent seizures. These seizures often originate from limbic networks and people also experience chronic comorbidities related to memory, mood, and sleep (MMS). Deep brain stimulation targeting the anterior nucleus of the thalamus (ANT-DBS) is a proven therapy, but the optimal stimulation parameters remain unclear. We developed a neurotechnology platform for tracking seizures and MMS to enable data streaming between an investigational brain sensing-stimulation implant, mobile devices, and a cloud environment. Artificial Intelligence algorithms provided accurate catalogs of seizures, interictal epileptiform spikes, and wake-sleep brain states. Remotely administered memory and mood assessments were used to densely sample cognitive and behavioral response during ANT-DBS. We evaluated the efficacy of low-frequency versus high-frequency ANT-DBS. They both reduced seizures, but low-frequency ANT-DBS showed greater reductions and better sleep and memory. These results highlight the potential of synchronized brain sensing and behavioral tracking for optimizing neuromodulation therapy.Competing Interest StatementUnrelated to this research, G.A.W., B.H.B., J.V.G., and B.N.L are named inventors for intellectual property developed at Mayo Clinic and licensed to Cadence Neuroscience. G.A.W. has licensed intellectual property developed at Mayo Clinic to NeuroOne. Mayo Clinic has received research support and consulting fees on behalf of G.A.W., B.N.L., and B.H.B. from Cadence Neuroscience, UNEEG Medical, NeuroOne, Epiminder, Medtronic, and Philips Neuro. P.C. has received research grant support from Neuronetics, NeoSync, and Pfizer; grant in kind (equipment support) from Assurex, MagVenture, and Neuronetics; and served as a consultant for Engrail Therapeutics, Myriad Neuroscience, Procter & Gamble, and Sunovion. T.D. is a consultant for Synchron, is on the advisory board of Cortec Neuro, is a shareholder collaborator of Bioinduction, and a shareholder director of Amber Therapeutics. All the other authors declare no competing financial interests.Clinical TrialNCT03946618Funding StatementThis work was supported by National Institutes of Health National Institute of Neurological Disorders and Stroke Grants UH2&3 NS095495, R01 NS112144 and U24 NS113637; Defense Advanced Research Projects Agency Grant HR0011-20-2-0028. The implanted devices were donated by Medtronic as part of the National Institutes of Health Brain Initiative. V.K. and V.S. were partially supported by institutional support of CTU in Prague.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of Mayo Clinic, Rochester, MN, USA gave ethical approval for this work (Mayo Clinic IRB: 18-005483)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe MRI, electrophysiology, and participant outcome data are available upon reasonable requests. A subset of awake, sleep, interictal and ictal continuous LFP recordings are available at the BNEL website.